Last reviewed · How we verify
Human Plasma
At a glance
| Generic name | Human Plasma |
|---|---|
| Also known as | non applicable |
| Sponsor | Ottawa Hospital Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
- Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption (PHASE2)
- The Body's Affect on Vitamin C (PHASE1)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring
- Histological Evaluation of Human Skin Bx to Assess the Effects of APR Tx as an Adjunct Procedure in Facelift Surgery (NA)
- suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
- Platelet Rich Plasma Injections In Young And Old Human Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Plasma CI brief — competitive landscape report
- Human Plasma updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI